About the Journal

Focus and Scope

Antibody Reports (ISSN 2624-8557) focuses on experimental validation of recombinant antibodies. The general aim is to define the specificity of an antibody and which detection techniques it is compatible with. Negative results, when including an adequate positive control, are also valuable. We encourage scientists to publish their experimental results in as much detail as possible, with the philosophy of "one antigen, one technique, one paper".

Open Access Policy

This journal is purely open access and provides immediate access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

Article Processing Charges

Antibody Reports is hosted by the University of Geneva and is technically supported by the Open Access Publication Service. It is partially supported by public funds and foundations. Our significantly reduced publication fees (CHF 300.-) contribute to covering the expenses associated with publication, including journal production and maintenance. Manuscripts featuring antibodies produced and/or discovered by the Geneva Antibody Facility will be published free of charge. Collaborators affiliated with the University of Geneva are also exempt from these charges.

Peer (Editorial) Review process

The review process for submissions to Antibody Reports follows a meticulous editorial evaluation.

Step 1: Upon receiving a manuscript, an academic editor with expertise in the field conducts a thorough initial quality check to assess its alignment with the journal's scope, the quality of content, and adherence to editorial policies and ethical standards. Submissions may be returned to authors for changes or clarifications at this stage.

Step 2: Once a submission is accepted, the editor proceeds to the reviewing phase with the aim of ensuring clarity of the data, scientific rigor, and compliance with our publication guidelines. The Editor-in-Chief, leveraging their expertise and insights from the editorial team, makes the final decision on whether to accept, revise, or reject the submission.

In our review model, the editor assumes the dual role of both reviewer and direct interactor with authors and the Editor-in-Chief. This approach establishes an open review identity and encourages interactive reviewing. It fosters direct reciprocal discussions between reviewers and/or between authors and reviewers, enhancing the collaborative nature of the review process.

Typically, the entire reviewing process takes an average of 20 days.

Publishing Schedule

Antibody Reports aims to maintain a continuous publication schedule, ensuring that articles are promptly published online as soon as they are ready, with the goal of achieving a rapid release, potentially on a daily basis. Since 2018, the journal has published an average of 28 articles per year, which are organized into archival 'issues' (at least 2 per year) and 'volumes' (one per year).

Archiving Policy

This journal ensures the long-term availability of its contents. Articles published in Antibody Reports are automatically deposited in the institutional repository of the University of Geneva, and from there, in the SAFE Private LOCKSS Network managed by 7 universities located on multiple continents, thus ensuring a very high level of preservation.
Antibody reports also encourages the self-archiving of articles after publication by their authors in open-access repositories of their choice, whether it is the submitted version, the accepted version, or the published version of the contribution.

Copyright Notice

Copyright for articles published in this journal is retained by the authors, with first publication rights granted to the journal. By virtue of their appearance in this open access journal, articles are free to use after initial publication under the Creative Commons Attribution 4.0 International licence (CC-BY).


This journal is published by the Bibliothèque de l'Université de Genève on behalf of the Geneva Antibody Facility.